WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997035580) ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/035580    International Application No.:    PCT/US1997/004800
Publication Date: 02.10.1997 International Filing Date: 25.03.1997
Chapter 2 Demand Filed:    25.09.1997    
IPC:
C07D 251/16 (2006.01), C07D 251/20 (2006.01), C07D 401/04 (2006.01)
Applicants: DU PONT PHARMACEUTICALS COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US)
Inventors: CHORVAT, Robert, J.; (US).
RAJAGOPALAN, Parthasarathi; (US)
Agent: BOUDREAUX, Gerald, J.; The du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US)
Priority Data:
60/014,213 27.03.1996 US
Title (EN) ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF
(FR) PYRIMIDINES ET TRIAZINES A SUBSTITUTION ARYLOXY ET ARYLTHIO ET DERIVES DE CELLES-CI
Abstract: front page image
(EN)The present invention provides novel compounds, and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsey, irritable bowl syndrome, immune supression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula (I) wherein R?1¿, R?3¿, R?5¿, Q, Z, Y, V, X and X' are as defined herein.
(FR)Nouveaux composés, compositions pharmaceutiques en dérivant et mode d'emploi de ceux-ci pour le traitement des troubles affectifs, de l'angoisse, de la dépression, du stress post-traumatique, des troubles alimentaires, de la paralysie supranucléaire, du syndrome du côlon irritable, de l'immunodépression, de la maladie d'Alzheimer, des affections gastro-intestinales, de l'anorexie nerveuse, des symptômes de sevrage des drogues et de l'alcool, de la toxicomanie, des troubles inflammatoires et des problèmes de fécondité. Les nouveaux composés qui font l'objet de la présente invention ont la formule (I) dans laquelle R?1¿, R?3¿, R?5¿, Q, Z, Y, V, X et X' sont définis dans la description.
Designated States: AU, CA, JP, MX, NZ.
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)